RDA Financial Network Has $1.72 Million Stock Position in Pfizer Inc. (NYSE:PFE)

RDA Financial Network grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 497.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 64,994 shares of the biopharmaceutical company's stock after buying an additional 54,124 shares during the period. RDA Financial Network's holdings in Pfizer were worth $1,724,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bradley Foster & Sargent Inc. CT grew its stake in shares of Pfizer by 3.2% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company's stock worth $7,586,000 after acquiring an additional 8,375 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its position in Pfizer by 0.6% in the second quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company's stock valued at $25,099,000 after purchasing an additional 5,246 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its stake in Pfizer by 1.4% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company's stock valued at $5,339,000 after buying an additional 2,572 shares during the last quarter. Blair William & Co. IL lifted its position in Pfizer by 85.9% during the 2nd quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company's stock worth $54,654,000 after buying an additional 902,376 shares in the last quarter. Finally, Sienna Gestion grew its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company's stock valued at $6,189,000 after acquiring an additional 1,771 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE traded down $0.19 during trading on Friday, hitting $26.30. 35,085,970 shares of the stock traded hands, compared to its average volume of 32,677,234. The business has a 50 day moving average price of $26.09 and a 200 day moving average price of $28.00. The company has a market cap of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.54%. Pfizer's dividend payout ratio is presently 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PFE shares. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 target price for the company. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target on the stock. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.